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Signaling cascades process extracellular information about environmental 
changes into spatiotemporally regulated signaling events, through a series of signal relays 
as well as feedback loops and crosstalk mechanisms. The JNK signaling cascade is a 
major mediator of vital cellular decision making processes, including cellular 
differentiation and inflammatory response. The cascade transduces a variety of 
extracellular signals into these functional responses, but its response to TNF, an 
important cytokine in immune system communications, has not been well characterized, 
especially at the single mammalian cell level. To characterize JNK quantitatively in 
single living cells, we used a FRET-based JNK activity reporter to visualize JNK activity 
in HEK cells. We found that JNK produces a graded response to varying concentrations 
of TNF, suggesting that JNK relays a graded input signal to its downstream components, 
which is subsequently converted into a digital response for executing important cellular 
decisions such as programmed cell death. Using the reporter targeted to the plasma 
membrane, we also discovered that JNK activation kinetics is slower at the plasma 
membrane compared to the cytosol, suggesting that JNK activities are regulated spatially. 
Moreover, JNK in HEK cells exhibited increased sensitivity to TNF when prestimulated 
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CHAPTER 1: INTRODUCTION  
  2 
1.1 Signaling Pathways 
 
Our bodies are constantly receiving, interpreting, and responding to external 
signals such as sounds and odors, and similarly, cells receive countless external cues with 
information about environmental changes, which are carried to different subcellular 
compartments through a series of intracellular signaling pathways. Signaling cascades 
process the information through a series of feedback loops, crosstalk mechanisms, and 
delays, which ultimately allows the cell to make important decisions. For instance, in 
response to external cues such as inflammatory cytokines, the information carried by 
these inflammatory cues gets processed to make the ultimate decision of whether the cell 
will undergo apoptosis. Recent human genome sequencing efforts have identified that 
approximately half of the twenty-five largest protein families encoded by the human 
genome primarily function in information processing and signal transduction [1]. 
Evidently, signal transduction is a widely relevant topic due to its overarching 
involvement in virtually all cellular processes, and its further understanding may 
eventually lead to the development of novel therapeutics against different diseases.  
Protein kinases play a major role in regulating signal transduction through 
phosphorylation of downstream targets, and ultimately cascading the signal from the 
extracellular environment to the targeted subcellular location. Specifically, the kinase in a 
tiered cascade modifies its substrates by chemically adding a phosphate group, thus 
producing a functional change in the substrate. 
1.2 c-Jun N-terminal kinase (JNK) Signaling Cascade 
A major player of signal transduction, and more specifically, a critical component 
of the cell’s apoptosis decision-making mechanism, is the c-Jun N-terminal kinase (JNK) 
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signaling cascade. JNK was identified in 1993 as an activating kinase of the c-Jun 
transcription factor, which spurred further characterization of the cascade. The JNK 
cascade is heavily involved in a variety of cellular events, including cell differentiation 
and cell inflammatory response due to its pivotal role in controlling apoptosis, making it 
an essential player in cellular decision making. JNKs have often been referred to as 
stress-activated protein kinases, as they respond to stress-inducing stimuli, including 
cytokines, UV radiation, ischemia, and growth factor deprivation [2].  
1.3 JNK Isoforms  
JNK consists of ten different isoforms generated through alternative splicing and 
derived from the three genes, JNK1, JNK2, and JNK3. JNK1 and JNK2 are ubiquitously 
expressed throughout the body, while JNK3 is tissue specific and is primarily present in 
the brain [3]. Knockouts of various combinations of the three JNK genes further elucidate 
specific functions of each gene and the importance of JNK to the cell. JNK1 knockout 
mice display decreased differentiation of helper T cells [4]. JNK1 has also been shown to 
play a major role in obesity and insulin resistance, as the absence of JNK1 resulted in 
increased resistance to high fat diet induced obesity and increased adiposity [5]. JNK2 
knockout mice also show deficiencies in helper T cell differentiation and have also been 
implicated to play a protective role for mice with Type I diabetes [4]. JNK1 and JNK2 
play similar roles in T cell differentiation, but only JNK1 has been implicated in obesity 
and insulin sensitivity. Lastly, JNK3 plays a role in neuronal cell death and brain 
development [5]. Kainate, which activates JNK in neuronal cultures, was used to induce 
apoptosis in JNK3 knockout mice, demonstrating that JNK3 knockout mice had 
decreased kainate-induced damage and higher survival rates compared to normal mice 
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[5]. Overall, although the three JNK isoforms have similar homology, they perform 
different, but very vital functions for the cell.  
Moreover, JNK double knockout studies demonstrated compensatory roles of the 
JNK isoforms. JNK1/3 and JNK2/3 knockouts were viable and functional, but JNK1/2 
were embryonically lethal and had dysregulation of apoptosis in the brain. Thus, JNK1 
and JNK2 plays a major role in the development of the fetal brain by controlling 
apoptosis [5]. 
1.4 JNK Regulation 
 
JNK is a subset of mitogen-activated protein kinases (MAPK), which are 
activated through cytokines and various stress stimuli through a three-tiered 
phosphorylation cascade (Figure 1-1). A stimulus instigates the activation of the upstream 
regulator, MAPKKK. Of the 20 MAPKKKs identified, 14 have been shown to activate 
JNK. The MAPKKK then proceeds to activate a MAPKK isoform through 
phosphorylation. For JNK, only two MAPKK isoforms, MAP kinase kinase 4 (MKK4) 
and MAPK kinase kinase 7 (MKK7), have been reported. Subsequently, these MAPKKs 
activate JNK by phosphorylating the Thr and Tyr residues of the TXY motif of the JNK 
activation loop. Upon activation, JNK translocates to the nucleus and modulates the 
activity of a variety of proteins, such as activating transcription factors c-Jun and 
activating transcription factor 2 (ATF2) or inhibiting signal transducer and activator of 
transcription 3 (STAT3). JNK’s ability to activate or inhibit a myriad of transcription 
factors allows JNK to regulate important cellular functions. 
1.5 JNK Activation 
 
The JNK cascade can be activated by several different stimuli, such as growth  
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factors, cytokines, and stress factors. Each of the many MAPKKKs is responsible for 
activation through different stimuli. For instance, the MAPKKK TAK1 is critical for 
activation in response to inflammatory cytokines, such as tumor necrosis factor, Toll-like 
receptors, B-cell receptor, and T-cell receptor [6-8]. 
1.5.1 Tumor Necrosis Factor α (TNF) Signaling 
 
TNF is a pleiotropic cytokine and a major mediator of apoptosis. Its dysregulation 
has been implicated in a variety of diseases, including Alzheimer’s and various cancers. 
TNF primarily regulates the cell’s immune response, but is involved in a variety of 
cellular functions and affects most of the organs in the body. TNF is produced by 
macrophages, fibroblasts, and lymphocytes in response to inflammation, and is often 
considered to be an anti-cancer agent. As a key intermediary in the cell’s inflammatory 
response, TNF has been implicated in cell apoptosis and its pathological activity and 
involvement in many diseases, including diabetes, cancer, multiple sclerosis and sepsis, 
has attracted much interest. TNF in the cell produces varying affects. For instance, high 
levels of TNF have been correlated with increased mortality rates [9], and mice without 
TNF experience septic shock when infected with gram negative bacteria. As a result of 
TNF’s pathological involvement, there is substantial interest in using TNF as a therapy 
against various cancers.   
TNF signaling begins when TNF binds to its cell surface receptor, either TNF 
receptor type 1 (TNFR1, p55) or TNF receptor type 2 (TNFR2, p75). TNFR1, expressed 
by most cells, is thought to be the main mediator of TNF cytotoxicity. TNFR1 can be 
fully activated through the membrane bound and soluble forms of TNF. TNFR2 is only 
found in immune system cells and only responds to the membrane bound form of TNF. 
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After TNF binds to TNFR1, the signaling cascade begins through the recruitment of 
signal transducers that then go on to activate downstream effectors, ultimately resulting 
in the activation of downstream targets, including two major transcription factors, c-Jun 
and nuclear factor-kB. When TNF binds to the extracellular domain of TNFR1, the 
receptor forms a trimer and this conformational change in the receptor causes the 
inhibitory protein, Silencer of Death Domains (SODD), to dissociate from the receptor, 
which subsequently allows TNF Receptor-Associated Death Domain (TRADD) to bind 
to the intracellular death domain. TRADD then recruits three other adaptor proteins, 
Receptor-Interacting Protein (RIP), TNFR Associated Factor 2 (TRAF2), and Fas-
Associated Death Domain (FADD). Subsequently, these three adaptor proteins recruit 
various enzymes that are responsible for initiating signaling cascades. Specifically, 
TRAF2 activates a MAPKKK, which then activates JNK cascade, resulting in the 
phosphorylation and increased activity of c-Jun. TNF produces the strongest activation of 
JNK, among the three major MAPK cascades of JNK, p38, and ERK.   
Although the JNK pathway has been extensively studied, the JNK response to 
TNF, an important cytokine in immune system communications, has not been well 
characterized, especially at the single mammalian cell level. Understanding this response 
can help uncover the role of TNF and JNK in cell death and the mechanisms behind it. 
1.6 Downstream JNK Targets 
 
Once JNK is activated through the cascade described above, it can proceed to 
phosphorylate and activate multiple downstream targets. Many of JNK’s nuclear 
substrates are transcription factors, allowing JNK to directly mediate cellular decision 
making through phosphorylation of these targets. In addition, the non-nuclear substrates 
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allow JNK to control other salient cellular behaviors, such as cellular movement and 
programmed cell death. JNK was first identified as an activator of transcription factor c-
Jun and is currently the only MAPK known to phosphorylate the N-terminal end of c-Jun. 
c-Jun has been heavily associated with cancer development, as it was found to be 
overexpressed in 31% of primary and metastatic lung tumors [10]. Other studies of 
hepatocellular carcinomas have also indicated that c-Jun is required for early stage tumor 
development, whereas c-Jun deletion suppresses tumor formation [11].  
1.7 JNK and Cancer 
 
The JNK pathway plays a multifaceted role in tumorigenesis, as it has been 
suggested to be both tumor suppressing as well as tumorigenic. First, there is substantial 
evidence that JNK functions as a proapoptotic kinase, promoting tumor suppression [12]. 
Multiple tumor cell lines possess constitutively active JNK [13], and several JNK family 
kinases have been shown to be involved in the biological process of regulating apoptosis 
in response to cellular injury [14]. JNK1/2 knockouts in mouse embryonic fibroblasts 
(MEFs) were resistant to apoptosis induced by UV irradiation, DNA-alkylating agent 
methyl methanesulfate, and translation inhibitor anisomycin [15] . This study suggested 
that the phosphorylation of c-Jun by JNK1 and JNK2 is required for UV-induced 
apoptosis. Moreover, JNK3 knockout mice were resistant to glutamate-induced apoptosis 
of hippocampal neurons, suggesting the major role of JNK3’s phosphorylation of c-Jun 
on excitotoxic cell death [15] . In all, all three JNK isoforms can play a pro-apoptotic 
role, but this role is often affected and determined by other cellular factors, including the 
parallel activation of anti-apoptotic pathways. Although many studies have identified 
JNK as a pro-apoptotic gene, JNK is not solely a pro-apoptotic kinase, as studies also 
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suggest JNK’s involvement in anti-apoptosis and cell survival. For instance, mice 
fibroblasts with a mutated c-Jun allele that lacks a JNK phosphorylation site is resistant to 
transformation induced by Ras, an oncogene that is mutationally activated in 
approximately 30% of human cancers, and Fos [13]. Furthermore, a mouse model of 
intestinal cancer with the c-Jun gene ablated, showed reduced tumor size and number and 
a prolonged lifespan. Furthermore, the hindbrain and forebrain regions of JNK1/2 
knockout
 
mice showed enhanced apoptosis at E10.5 [16, 17], suggesting JNK’s 
involvement in cell survival of those regions of the brain during development. The anti-
apoptotic involvement may also result in enhancement of tumorigenesis. When JNK 
activation is inhibited by anti-sense oligonucleotides, the growth of several tumor cells 
was also inhibited [18]. Not only JNK, but also its directly upstream pathway component, 
Mitogen-Activated Protein Kinase Kinase 4, has also been involved in several cancer 
studies, and demonstrated a similarly complex role [6, 19-24]. Overall, JNK and its 
pathway components have been heavily implicated in cancer, but it’s role and mechanism 
in apoptosis and tumorigenesis is unclear.  
These findings do not demonstrate whether JNK is an intrinsic component of the 
cell’s apoptosis machinery, or whether it solely modulates the process [12]. Studying the 
molecular mechanism of JNK in regulating and modulating apoptosis will allow clearer 
understanding of JNKs role in apoptosis and cellular decision making. Several drugs that 
target JNK have been developed and have shown to be effective at protecting mice from 
Type 2 diabetes and tissue injury from ischemic disease. Through developing a deeper 
understanding of the JNK pathway mechanism, JNK may be used towards the 
development of novel targeted therapies for the prevention or treatment of human 
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diseases due to JNKs widespread role in programmed cell death and cancer. 
1.8 Spatial Compartmentalization of Signaling Proteins 
1.8.1 Introduction 
 
 Protein kinases, including JNKs, are often referred to as the intermediate nodes 
that connect upstream stimuli to produce downstream cellular responses. The mechanism 
by which the kinase processes the signal information results in vital cellular decision 
making downstream, such as whether to undergo apoptosis or to induce gene expression. 
Since these kinases are often responsible for diverse functional outputs, modulating 
various signaling events often requires tight spatiotemporal control of kinase activities to 
elicit specific functional outputs. For instance, in many signaling cascades, scaffolding 
proteins are heavily involved in signal transduction process, often by enhancing the 
specificity of the relay process and increasing the signal efficiency by concentrating the 
signaling components locally. Thus, to accurately determine dynamic signaling behavior, 
the cascade must be analyzed with all its cellular regulatory components intact. 
Specifically, for example, the Western blot technique is commonly used to analyze the 
activity and presence of protein kinases subject to various stimuli, but this approach only 
provides snapshots of averaged signal from lysed cells and cannot capture dynamic 
kinase behavior in live cells. As a result, there is substantial need for an approach to study 
protein kinases with all of the cell’s regulatory mechanisms intact, and without altering 
the spatial compartmentalization of the kinases or its mechanism of action within the cell. 
In addition, the protein kinetics should also be investigated at the single cell level. 
Population level dynamics often average out important signal transduction events, such as 
oscillatory activities or bistable responses.  
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1.8.2 Novel Method to Study the Spatiotemporal Regulation of Signaling Proteins: 
Fluorescence Resonance Energy Transfer (FRET)-Based Biosensors 
 
Although several fluorescent biosensors have been created for various signal 
transduction events, such as changes in membrane potential [25], up until recently, it has 
been difficult to obtain quantitative live cell data for the activity of protein kinases. An 
innovative method to examine the single cell, quantitative dynamics of protein kinases 
with high spatial and temporal resolution is based on fluorescence resonance energy 
transfer (FRET). FRET is the transfer of energy from an excited donor fluorophore to an 
acceptor fluorophore. Due to recent significant progress in improving fluorescent proteins 
and the increased availability of fluorescent protein color variants, fluorescent protein 
FRET pairs can now be coupled with different sensing modules to create FRET-based 
reporters that can sense dynamic activity changes in single, living cells.  
The efficiency of the energy transfer is inversely proportional to the sixth power 
of the distance between the fluorophore pair, as FRET is extremely sensitive to the 
distance and orientation of the donor and acceptor fluorophores, and the energy transfer 
will only occur when the two fluorophores are 1-10 nm apart. The efficiency of FRET is 
also determined by spectral overlap of donor emission and acceptor excitation peaks, and 
acts as a sensitive measurement of molecular events such as protein-protein interactions, 
or changes in protein conformation. The fluorophore pair selected for FRET must also 
have separate excitation and emission in order to prevent signal bleedthrough and 
fluorophore cross excitation. The most commonly used FRET pair is yellow fluorescent 
protein (YFP) and cyan fluorescent protein (CFP) due to their high level of spectral 
overlap. Provided that the two fluorescent proteins are in close proximity, excitation of 
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the donor fluorophore, CFP, with a wavelength of 430 nm, will results in the emission of 
the acceptor fluorophore, YFP, at a wavelength of 515 nm, due to energy transfer.  
The general design of genetically encoded kinase activity reporters is essentially a 
kinase activity-dependent molecular switch sandwiched between two fluorescent proteins 
that can undergo FRET (Figure 1-2). The switch consists of a substrate domain, and a 
phosphoaminoacid binding domain. Biosensors that report on kinase activity are 
constructed based on three major concepts. First, the substrate domain must be specific to 
the kinase to be studied. Second, the phosphoaminoacid binding domain must be 
compatible with the substrate sequences, and may need to be modified with point 
mutations to fit the requirements. Third, sufficient linker regions between each of the 
components must be present, and can also be optimized to enhance the dynamic range 
and stability of the reporter [26]. Upon satisfying these conditions, when a specific kinase 
of interest phosphorylates the substrate domain, the phosphoaminoacid binding domain 
can bind the phosphorylated substrate, changing the distance and/ or orientation of the 
two fluorophores from the FRET pair, resulting in a FRET change. The FRET based 
reporter can easily be introduced into living cells and can even be fused with localization 
signals to target a specific, subcellular location. 
1.8.3 JNK Activity Reporter 2 (JNKAR2) Probe 
 
 JNK Activity Reporter 1 (JNKAR1), a live cell JNK activity reporter, has been 
created using these criteria [27]. In the design of JNKAR, the docking domain from a 
known JNK substrate JDP2 recruits JNK, which phosphorylates the substrate domain, 
also a sequence from JDP2, which causes the phosphoaminoacid binding domain to 
intramolecularly bind the phosphorylated JDP2 domain, resulting in the conformational  
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change of the reporter. This subsequently causes a change in the FRET emission from the 
two sandwiching fluorescent proteins, eCFP (a CFP) and Citrine (a YFP), and this change 
in fluorescence can easily be detected with fluorescence microscopy of cells expressing 
the probe. JNKAR1 generated a relatively modest 20.0% FRET change upon stimulation 
with a ribotoxic drug, anisomycin. A larger dynamic range should increasd probe 
sensitivity. Therefore, an improved reporter with a higher dynamic range, JNKAR2 (JNK 
Activity Reporter 2), was generated. The FRET pair used in the design of the JNKAR2 
probe is Venus, a monomeric YFP variant, and Cerulean, a more photostable and brighter 
variant of CFP (Figure 1-3A) [28]. JNKAR2 can also be targeted to track JNK activity at 
subcellular locations, such as the mitochondria, plasma membrane, and nucleus, by 
fusing the probe with specific targeting motifs. The plasma membrane targeted JNKAR2 
construct is shown in Figure 1-3B.  
Previous findings demonstrate that JNK responds to stimuli in an all or none 
manner in oocytes, but these studies were conducted at the population level, and single 
cell data especially in mammalian cells has not been attainable until now. HeLa cells 
expressing the JNKAR1 probe were treated with varying concentrations of anisomycin 
stimulus and the normalized emission ratio, which shows the JNK activity, suggest that 
JNK activation is all or none in HeLa cells with anisomycin stimulation [27]. The 
improved probe, JNKAR2, now allows us to study the spatiotemporal changes of JNK 














As a cell receives signals from the external environment, it is able to process 
information and execute many vital cellular decisions. The cell essentially takes a 
continuous input signal, such as the concentration of a stimulus, and converts it into a 
discrete response. The cell’s response varies based on the type and concentration of 
stimulus, but typical responses include the production of secondary messengers or 
activation of protein kinases, both of which further relay the signal to downstream 
targets, to ultimately make vital decisions such as whether to proliferate or undergo 
apoptosis. A major question today concerns where that “switch” occurs during signal 
processing, as modulation of signal transduction activity has proven to be a common 
initiation point for switch-like behavior [29, 30]. The JNK signaling cascade transmits a 
vast variety of extracellular information that results in important cellular responses. 
JNK’s ability to differentiate between the various external stimuli and induce the 
appropriate response is vital; otherwise, cells will indiscriminately respond to different 
stimuli, preventing the correct execution of crucial cellular processes. Many of the details 
of the JNK pathway are unknown, such as whether the JNK cascade converts a 
continuous input signal into a discrete response. As a result, understanding whether the 
JNK cascade processes these inputs by producing graded or bistable responses may 
elucidate the role of JNK in apoptotic signaling. If the JNK cascade transmits graded 
information from upstream activators, then the apoptosis decision is likely made 
downstream of JNK, since apoptosis is an all-or-none event. In contrast, if the JNK 
cascade exhibits bistable character, then JNK may likely be converting a graded input 
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into a switch like response, filtering out noise and generating an ultrasensitive response, 
and relaying this all or none signal to downstream effectors.  
Previous experiments to study JNK’s response were conducted in Xenopus 
oocytes because of their large size, allowing the signal transduction events to be assessed, 
because oocytes can be both pathologically and physiologically activated, and because of 
the availability of quantitative techniques to analyze the signal transduction events of this 
system [31]. These studies investigated the JNK response to progesterone, a 
physiological stimulus, and sorbitol, a hyperosmolar pathological stress. Progesterone 
works through the Mos  MEK  p42 MAPK cascade and can bring about JNK 
activation, whereas sorbitol activates JNK without going through p42. In pools of oocytes 
stimulated with progesterone, the JNK activity was graded as a function of progesterone 
concentration, with a Hill coefficient of 1 [31]. However, a graded response at the 
population level can have two interpretations regarding the cells behavior at the 
individual level. The first being that the individual oocytes in the population all produce a 
graded response to the stimulus, and the second being that the individual oocytes produce 
bistable responses, but have different thresholds for activation, resulting in a graded 
response at the population level when all individual responses are averaged out. To 
uncover which explanation is accurate, the JNK response of individual oocytes was 
examined. Individual oocytes exhibited a bimodal distribution, with minimal oocytes 
exhibiting intermediate JNK activity [31]. These findings reiterate the importance of 
having a method to analyze signal processes at the single cell, quantitative level, as 
population based results are often not representative of behavior on the single cell level. 
Furthermore, JNK exhibits an all-or-none response to sorbitol at the individual as well as 
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population level, indicating that unlike the JNK response to progesterone, the response to 
sorbitol has minimal variability in the threshold to activation [31]. These results conclude 
that the all or none activation of JNK in oocytes is not solely limited to the p42 pathway, 
but is likely intrinsic to the JNK cascade in oocytes. 
In general, all-or-none responses are the result of either an ultrasensitive signaling 
cascade, or a bistable signaling cascade. The latter exhibits hysteresis since the response 
depends on its history [32]. In the case of hysteresis, once the stimulus surpasses a 
threshold, the cascade will switch on and be maintained in the on state even when the 
stimulus falls well below the threshold concentration. In the oocyte study above, the 
researchers proposed that JNK in oocytes likely exhibited bistability with hysteresis. To 
determine this feature, the oocytes were stimulated with sorbitol, and then the stimulus 
was subsequently washed away, while continuing to observe the JNK response of the 
oocyte. The results illustrated that approximately 70% of the oocytes remained fully 
active for as long as 16 hours after removal of sorbitol [31]. The persistence of the JNK 
activity suggests the presence of hysteresis. Overall, these findings suggest that the JNK 
cascade of oocytes exhibits switch-like behavior, converting the graded input of stimulus 
concentration into a bistable, all-or-none response.  
The major difference between a biological system with a bistable response and 
one with a graded response lies in the system design of how the system components are 
connected. For instance, the lac operon system can switch between a graded and a 
bistable state, simply depending on the presence or absence of the physiological inducer 
lactose [32]. In the presence of the physiological inducer lactose, the internal inducer 
allolactose is destroyed by the induced product, stopping the positive feedback loop and 
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converting the switch like output into a graded output. In all, studying the system design 
of signaling cascades helps explain the information processing mechanism of these 
pathways, and elucidates how they influence important cellular decision making 
mechanisms. 
Current knowledge of the JNK response has mainly been on the population level, 
studied in oocytes, or investigated with non-physiological stimuli such as anisomycin in 
the JNKAR1 study. The development of the novel JNKAR2 probe enables the study of 
single cell, quantitative data of JNK activity in living cells, induced by physiological 
stimuli due to the probe’s increased dynamic range. Therefore, by investigating the JNK 
response in mammalian cells, we aim to develop a clearer understanding of the 
physiological JNK signal transduction mechanism, which may ultimately provide insight 
into how and where a cell makes the decision to undergo proliferation or apoptosis.  
2.2 Materials and Methods 
 
Cell Culture 
HEK cells were cultured in DMEM with 10% fetal bovine serum. Cells were 
transfected in 35mm dishes with Trans-IT 2020 transfection reagent (Mirus Bio) for 
untargeted JNKAR2 and transfected with Lipofectamine 2000 (Invitrogen) for plasma 
membrane targeted JNKAR2. All cells were imaged 36-48 hours after transfection. 
Imaging 
JNKAR2 expressing cells were serum starved in DMEM F12 with 0.1% fetal 
bovine serum 10-12 hours prior to imaging, and imaged in the same media. These cells 
were imaged in 8-well chamber slides (Lab-Tek) coated with fibronectin with a Zeiss 
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Axiovert 200M using a cascade CCD camera (Photometrics) and 40x oil immersed lens 
at 37C and 5% CO2, controlled by SlideBook (Intelligent Imaging).  
Plasma membrane targeted JNKAR2 expressing cells were serum starved in 
DMEM F12 with 0.1% fetal bovine serum 10-12 hours prior to imaging, and then washed 
with Hanks’ Balanced Salt Solution (HBSS) buffer and also imaged in HBSS. Plasma 
membrane targeted JNKAR2 expressing cells were plated onto sterilized glass coverslips 
that were mounted in 35mm dishes. These cells were imaged with a Zeiss Axiovert 
microscope with a CCD camera (Roper Scientific), controlled by METAFLUOR 
software (Universal Imaging). 
2.3 Results 
 
2.3.1 JNK Dose Response 
 
The JNKAR2 construct was first characterized in HEK cells transfected with the 
JNKAR2 probe and stimulated with 5 ng/mL of human TNF. These cells exhibited a 29.1 
± 12.6% (average ± STD, n = 24) increase in FRET to cyan emission ratio (Figure 2-1). 
This probe exhibits a 45.5% increase in dynamic range compared to the JNKAR1 probe 
[27], as a result of changing the fluorescent pair used in the reporter. Physiologically, 
JNK activity generally increases 25-fold within the first ten minutes of TNF stimulation 
[33, 34]. The probe begins to exhibit a rapid change in FRET to CFP emission ratio 12.25 
± 6.50 minutes (n=24) after 5.0 ng/mL stimulation, suggesting that the probe has a slight 
delay in showing JNK activity. 
To examine the JNK dose response, quantitative single cell analysis was 
performed by stimulating HEK cells expressing the novel JNKAR2 reporter with varying  
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concentrations of TNF, ranging from 0.005 to 5.0 ng/mL. At the highest dose of 5.0 
ng/mL, 100% of cells fully responded to TNF stimulation. At the intermediate doses of 
0.5 and 0.05 ng/mL, there was a wide cell-to-cell variation in emission responses, 
including maximal response, many intermediate responses, and no response. JNK activity 
in each cell varied and appeared to be highly dependent on the dose of TNF administered. 
At the lowest dose of 0.005 ng/mL of TNF, the majority of cells did not exhibit an 
increase JNK activity after exposure to stimulus. Representative curves from the four 
doses are displayed in Figure 2-2. Two distinct populations of responses were not 
present, indicating that the JNK response to TNF is not ultrasensitive. Specifically, the 
average response at the intermediate doses, 13.26% for 0.05 ng/mL TNF and 16.73% for 
0.5 ng/mL TNF, cannot be defined as having the same response level as that of the lowest 
dose at 9.58% or that of the highest dose at 29.13% (Figure 2-2 B, C). The high standard 
deviation values when calculating the average percent FRET response for the 
intermediate doses in Figure 2-2C results from cell-to-cell variation in response strength, 
ranging from maximal response identical to those seen in the 5.0 ng/mL TNF stimulation 
to no response, similar to the representative curve for the 0.005 ng/mL stimulation. 
The responses at each stimulus concentration can be grouped into three categories 
(Figure 2-3). The distribution of cells in these three categories varies based on the dose of 
TNF used. As the stimulus concentration increases, the percentage of cells exhibiting 
maximal response increases from 0 to 100%, whereas the percentage of cells with 
minimal or no response decreases from 58.8 to 0%.  
Furthermore, the stimulus strength also impacts JNK activation kinetics. The JNK 




reach half the maximal response (t1/2). The t1/2 was 60.5 ± 17.87 minutes (n=8) for 0.005 
ng/mL TNF, 42.0 ± 21.5 minutes (n=13) for 0.05 ng/mL TNF, 33.64 ± 10.68 minutes 
(n=14) for 0.5 ng/mL TNF, and 14.17 ± 5.90 minutes (n=24) for 5.0 ng/mL TNF. The t1/2 
decreases as the stimulus concentration increases, indicating faster JNK activation 
kinetics when cells are subjected to higher concentrations of TNF (Figure 2-4).  
2.3.2 JNK Plasma Membrane Localization 
 
Investigating the cellular localization and spatial regulation of JNK within the cell 
is vital to fully understanding the JNK mechanism. Several JNK responses have been 
shown to either originate or be mainly prevalent in a specific region of the cell. For 
instance, cardiomyocyte cell death can be induced by JNK mitochondrial signaling [35]. 
Overall, JNK can phosphorylate physiological substrates in different subcellular locations 
and the activation kinetics and differences between TNF-induced JNK activities in these 
different areas of the cell have not been systematically analyzed.  
To analyze JNK activity dynamics at the plasma membrane, we performed 
quantitative single cell analysis by stimulating HEK cells expressing the plasma 
membrane targeted JNKAR2 probe with 5.0 ng/mL hTNF. The average response was a 
16.10 ± 8.62% (n=12) increase in upon stimulation (Figure 2-5). All cells responded to 
the stimulation, but with highly varying amplitudes. These results indicate that TNF can 
facilitate JNK activity at the plasma membrane.  
Furthermore, the kinetics of JNK activation at the plasma membrane, calculated 
as t1/2, was 34.92 ± 9.01 minutes (n=24). This 146.61% increase in t1/2 compared to whole 
cell JNKAR2 with the same stimulus concentration clearly indicates that JNK at 
subcellular locations exhibit different activation dynamics. The increase in t1/2 is due to 
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Figure 2-4. Faster JNK response at higher TNF concentration 
 
The JNK response of HEK cells when subjected to increasing doses of TNF subsequently 
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both a slower rise in FRET emission ratio as well as a delayed start to activation, as 
shown from representative curves in Figure 2-6. The delayed activation at the plasma 
membrane indicates that JNK activity upon activation is not uniform throughout the cell. 
JNK may be sequestered within the cytoplasm, leading to the faster response in the 
cytosol and postponing the activation in the plasma membrane. Alternatively, JNK may 
need to interact with other proteins prior to reaching the plasma membrane, resulting in 
the delay. For instance, in fibroblast growth factor-2 (FGF2) activation of JNK, JNK has 
been found to translocate to the plasma membrane after being recruited by the scaffold 
protein, JNK/ stress-activated protein kinase-associated protein 1 (JSAP1) [36].  
2.4 Discussion 
 
JNK signaling is widely involved in a plethora of cellular processes. Up until recently, its 
mechanism of action during the cell’s decision making process has been ambiguously 
defined. However, the recently developed JNKAR2 probe allows us to analyze JNK 
activity at the single cell level, within the cell’s native environment at high signal-to-
noise ratios. An analysis of the FRET emission using this probe indicates that the JNK 
response to TNF in HEK cells likely does not exhibit switch-like behavior in response to 
TNF stimulation, but rather relays the graded signal from the input to JNK’s downstream 
effectors to interpret and convert into a digital signal for subsequent execution of 
important decisions.  
Moreover, studying the subcellular localization of JNK provides insight into the 
spatiotemporal regulation of JNK throughout the cell. Evidently, JNK activation at the 
plasma membrane is both slower and delayed compared to that of the whole cell. These 
findings demonstrate that once JNK is activated, it does not immediately distribute 
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uniformly throughout the cell, but rather reaches subcellular locations at varying time 
points. Further analysis of the JNK response at other subcellular locations, including the 
mitochondria and the nucleus may elucidate more into the subcellular localization of JNK 
within the cell. 
Additionally, important characteristics such as JNK’s sensitivity to repeated 
stimuli have yet to be determined. Bistable signaling has frequently been described as a 
characteristic of signaling pathways [37], but these findings oppose this hypothesis, 
previous findings in the oocyte maturation process [31], as well as HeLa cells subjected 
to anisomycin stimulation [27]. Thus, the JNK pathway response is likely dependent on a 
variety of factors including the cell line and the stimulus, emphasizing that the 
mechanism by which JNK processes graded input signals is still extremely ambiguous. 
The JNKAR2 probe provides a unique opportunity to further study the JNK mechanism 











Although TNF is a pivotal cytokine that regulates the cell’s immune response, its 
tolerance and sensitivity in mammalian cells to repeated TNF stimulation is unknown. 
Tolerance to the toxic effects induced by TNF has been found to develop after repeated 
administration of low doses of TNF in rats, as selective TNF effects are reduced 
following repetitive stimulus administration [38]. However, the mechanism by which this 
tolerance develops is unclear and has also not been investigated in mammalian cells.  
Furthermore, cells must make critical decisions to determine a specific cell fate in 
the presence of noisy signals. A true signal is the intended change, for example in the 
stimulus concentration, whereas noise is stochastic fluctuations. The mechanism by 
which cells are able to reliably detect and respond to the true stimuli lies in the sensitivity 
of the cell to concentration changes of the stimuli input signal. Because random 
fluctuations in the signal concentration are often present, the cell must utilize its signal 
processing mechanism to delineate between noise and the intentional signal. Therefore, 
understanding the sensitivity and tolerance of a signaling cascade to input signals such as 
TNF, can provide vast knowledge into the cell’s immune response, the mechanism of the 
JNK pathway, and how the cascade will react and execute information given by the 
stimulus.  
3.1.1 Receptor Sensitization and Desensitization 
 
 Continued or repeated stimulation of a signaling receptor by its agonist can lead 
to changes in the receptor responsiveness. These changes can be categorized as either 
sensitization or desensitization. Receptor sensitization is the concept that repeated 
stimulus administration will result in amplification of response, as for example more 
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receptors to that stimulus will move to the surface in anticipation of an incoming 
stimulation. In contrast, receptor desensitization occurs when a receptor’s response to a 
stimulus is decreased after repeated stimulation for example due to a decrease in the 
number of receptors at the cell surface. These two phenomena have been identified in 
many signaling processes. For instance, in the repeated stimulation of cyclic AMP 
(cAMP) by its agonist, cAMP levels plateau or even return to basal levels within minutes 
of continued exposure [39]. 
In this section we investigate the tolerance and sensitivity of HEK cells in 
response to TNF by quantifying the JNK response to a single dose of TNF stimulation 
compared to that of two repeated doses of TNF stimulation using the JNKAR2 probe to 
track and provide quantitative single cell data. Specifically, we would like to determine 
whether the JNK pathway in response to TNF displays receptor sensitization or 
desensitization by looking at the kinetic differences in the responses.  
3.2 Materials and Methods 
 
Cell Culture 
HEK cells were cultured in DMEM with 10% fetal bovine serum. Cells were 
transfected in 35mm dishes with Trans-IT 2020 transfection reagent (Mirus Bio) and 
imaged 36-48 hours later.  
Imaging 
Cells were serum starved in DMEM F12 with 0.1% fetal bovine serum 10-12 
hours prior to imaging, and imaged in the same media. Cells were imaged in 8-well 
chamber slides (Lab-Tek) coated with fibronectin with a Zeiss Axiovert 200M using a 
  35 
cascade CCD camera (Photometrics) and 40x oil immersed lens at 37°C and 5% CO2, 
controlled by SlideBook (Intelligent Imaging). 
3.3 Results 
 
HEK cells transfected with the JNKAR2 probe were first stimulated with 0.05 
ng/mL TNF, one of the intermediate concentrations used in the dose response results of 
Chapter 2, for 42 minutes, and then immediately stimulated with additional TNF to reach 
a final dose of 5.0 ng/mL TNF. To emphasize the presence of three separate responses to 
three different stimulation doses (no TNF, 0.05 ng/mL TNF and 5.0 ng/mL TNF), other 
types of responses, such as cells that displayed no change in JNK activity upon initial 
stimulation, were excluded from the analysis. A representative time course emission ratio 
illustrating JNK activity throughout the experiment is shown in Figure 3-1. The cell 
responds with a slow and gradual rise in JNK activity after the initial stimulation, with a 
9.00 ± 4.68% (n=10) increase in FRET emission ratio, similar to the results of the 0.05 
ng/mL TNF stimulation in Chapter 2 as expected. This response was followed by a rapid 
rise and subsequent plateau in JNK activity upon stimulation with a total dose of 5.0 
ng/mL TNF, which resulted in a 26.14 ± 10.95% (n=10) increase in emission ratio, when 
normalized to the timepoint immediately preceding 5.0 ng/mL stimulation.  
The results further validate that HEK cells stimulated with TNF illustrate a graded 
response. The initial stimulation cannot be categorized as a bistable, all or none JNK 
response, but instead elicits an intermediate level of slowly rising JNK activity. The 
representative time course clearly portrays three distinct JNK responses—no activity 
when no stimulus is present, intermediate and slowly increasing JNK activity with 0.05 
ng/mL stimulation, and high activity level with 5.0 ng/mL stimulation.  
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Moreover, the second stimulation with the 100-fold greater dose of TNF changes 
the percent FRET change as well as produces altered JNK activity kinetics compared to  
the same stimulation dose alone. A comparison of the average percent change in yellow 
FRET to cyan emission ratio between the 5.0 ng/mL TNF stimulation with prestimulation 
of 0.05 ng/mL TNF and the 5.0ng/mL TNF stimulation alone indicates that the presence 
of prestimulation produces a greater change in emission ratio, and thus a heightened level 
of JNK activity (Figure 3-2 A,B). Furthermore, an analysis of the time to half maximal 
JNK activity for the two sets of experimental conditions portrays important differences in 
the activation kinetics (Figure 3-2 A,B). Overall, the 20.53% increase in percent FRET 
change and the 20.96% decrease in t1/2 when compared to no prestimulation, clearly 
demonstrate that by initially pretreating the HEK cells with a low dose of TNF, the 
response to a subsequent dose elicits a greater and quicker response, possibility due to 
increased sensitization of the TNF receptors at the cell surface. 
3.4 Discussion 
 
Evidently, pretreatment of HEK cells with a low dose of TNF elicits an altered 
JNK response in both the level of JNK activity as well as the activation kinetics. These 
findings elucidate information about the JNK pathway’s tolerance and sensitivity in HEK 
cells in response to TNF. In HEK cells, initial stimulation with low dose of TNF followed 
by stimulation with a higher dose does not result in tolerance, but rather displays 
increased sensitivity to the stimulus, as demonstrated by the faster activation kinetics and 
increased level of JNK activity. Tolerance may develop following additional repeated 
stimulation at a low dose of TNF, but two TNF doses in close temporal proximity does  
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not result in tolerance to TNF’s effects on the JNK pathway of HEK cells. These findings 
suggest receptor sensitization of TNFR1 to repeated TNF stimulation.  
The mechanisms underlying such sensitization are currently unknown. It is 
possible that the receptor levels of biochemical states change in response to the first dose. 
The initial dose of TNF may cause an excess amount of TNFR1’s to move to the cell 
surface in anticipation for incoming TNF stimulus. Other possible mechanisms may 
involve crosstalk between the JNK signaling pathway and other pathways. Previous 
findings have demonstrated that the TNFR1 induced apoptotic signaling pathway results 
in the formation of two distinct signaling complexes. The initially formed complex I at 
the plasma membrane rapidly triggers an NF-κB cell survival response, whereas the 
subsequently formed complex II involves FADD and procaspases, but not TNFR1, and 
develops in the cytoplasm [40]. Activation of complex II results in programmed cell 
death when the NF-κB cell survival signal from complex I fails to induce expression of 
anti-apoptotic proteins. Studies have also investigated the crosstalk between TNF-
induced NF-κB and JNK pathways and its regulation on cell fate determination. The level 
of JNK activation from TNF stimulation appears to be regulated by NF-κB activation. 
Future research can examine whether the first dose of TNF induces any changes to the 









CHAPTER 4: CONCLUSIONS 
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Using a genetically encodable FRET-based biosensor for JNK, we were able to 
characterize the JNK cascade in response to TNF stimulation. Our results indicate that 
HEK cells stimulated with TNF elicit a graded JNK response. These findings strongly 
suggest that the characteristics of the JNK response vary depending on cell line and 
stimulus, as HeLa cells subjected to anisomycin and oocytes stimulated with sorbitol and 
progesterone both exhibit a bistable response to graded input signals [37]. Moreover, the 
JNKAR2 probe also allows study of JNK’s subcellular localization in areas such as the 
plasma membrane. Comparing the kinetics of JNK activation of whole cell JNKAR2 and 
plasma membrane targeted JNKAR2, we found that JNK activation is delayed at the 
plasma membrane. Further investigation of JNK subcellular localization can reveal more 
about the spatiotemporal regulation of JNK upon activation with stress stimuli. Lastly, by 
pretreating HEK cells with a lower dose of TNF, a subsequent TNF stimulation exhibits a 
faster and increased JNK response, suggesting that JNK signaling can be sensitized. 
Overall, the JNKAR2 probe has allowed us to characterize JNK activity under tight, 
complex spatiotemporal regulation and further investigation of JNK activation dynamics 
can be conducted using the novel FRET-based probe to investigate how the JNK 
response varies across different cell lines and subjected to various physiologically 
relevant stimulation. Due to JNK’s vast involvement in vital cellular decision making 
such as cellular apoptosis and differentiation, investigating its response to immune 
system stimulus, such as TNF as seen here, can provide significant insight into the 
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